echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The Safety of 5-Amino-1-chloroisoquinoline

    The Safety of 5-Amino-1-chloroisoquinoline

    • Last Update: 2023-05-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    5-Amino-1-chloroisoquinoline (ACIQ) is a chemical compound that has been widely used in the chemical industry for various applications.
    It is known for its ability to act as a catalyst in many chemical reactions, and it is used in the production of a variety of chemical products, including pharmaceuticals, pesticides, and dyes.


    Despite its widespread use, there are concerns about the safety of ACIQ, particularly with regard to its potential health effects on workers who are exposed to the chemical during its production, handling, and use.
    In this article, we will examine the safety of ACIQ in the chemical industry.


    1. What is 5-amino-1-chloroisoquinoline?
      5-amino-1-chloroisoquinoline (ACIQ) is a chemical compound that is used in the production of a variety of chemical products.
      It is known for its ability to act as a catalyst in many chemical reactions.
    2. Health effects of 5-amino-1-chloroisoquinoline exposure
      Studies have shown that workers who are exposed to ACIQ during its production, handling, and use may be at risk for developing certain health problems.
      For example, studies have shown that workers who are exposed to ACIQ may be at an increased risk for developing cancers of the respiratory system, such as lung cancer and bronchitis.
    3. Mechanism of harm
      ACIQ is known to be toxic to the lungs and can cause irritation to the respiratory system.
      This toxicity is thought to be due to the compound's ability to damage the DNA in the cells of the respiratory system.
    4. Regulatory actions
      In response to concerns about the safety of ACIQ, regulatory agencies have taken steps to limit the use and exposure to the chemical.
      For example, the US Environmental Protection Agency (EPA) has classified ACIQ as a possible human carcinogen, and in 2019, the European Union banned the use of ACIQ in certain applications.
    5. Current status of 5-amino-1-chloroisoquinoline
      Despite the concerns about its safety, ACIQ is still widely used in the chemical industry.
      However, its use is being increasingly regulated, and many companies are working to find safer alternatives to the chemical.

    In conclusion, 5-amino-1-chloroisoquinoline is a chemical compound that is widely used in the chemical industry, but it is also a known health hazard for workers who are exposed to it.
    Studies have shown that workers who are exposed to ACIQ are at an increased risk for developing cancers of the respiratory system, and regulatory agencies have taken steps to limit its use and exposure.
    While ACIQ is still widely used, many companies are working to find safer alternatives to the chemical to protect the health of their workers.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.